4 results about "Pranlukast" patented technology

The present invention relates to a pharmaceutical composition for improving the bioavailability of pranlukast and a method for preparing the same, and more particularly, to a pharmaceutical composition for improving the bioavailability of pranlukast, which comprises 0.1 to 10 parts by weight of a water-soluble polymer and 0.1 to 5 parts by weight of a flow aid such as silicon dioxide, relative to 15 to 25 parts by weight of pranlukast, so that the composition of the present invention exhibits bioequivalent or even superior pharmacokinetic characteristics to a commercially available preparation even when the content of pranlukast is reduced to 50 mg or less per tablet (1 tablet per time, twice a day), thereby improving the medication compliance of patients and reducing side effects caused by the intake of an excessive amount of pranlukast, and a method for preparing the same.

The application provides a method for determining the content of pranlukast, which is suitable for the technical field of quality control of organic chemical synthetic bulk drugs, and especially suitable for accurate content detection in the production process of pranlukast bulk drugs. The analysis method overcomes the limitations of tailing and asymmetry of pranlukast chromatographic peak in the prior art, optimizes the composition of the mobile phase and the chromatographic conditions, shortens the analysis time, and improves the detection sensitivity and accuracy. The application adopts high performance liquid chromatography, the chromatographic column is a silica gel bonded octadecylsilane column, the ultraviolet detector is used, the mobile phase is a phosphate buffer solution containing ion pair reagent sodium heptanesulfonate and an organic solvent acetonitrile, and the separation and detection are carried out in an isocratic elution mode. The method has good separation degree, strong specificity, high precision and good repeatability, and meets the methodological verification requirements of the content determination of pranlukast.

The present invention relates to a pharmaceutical composition for improving the bioavailability of pranlukast and a method for preparing the same, and more particularly, to a pharmaceutical composition comprising 0.1 to 10 parts by weight of a water-soluble polymer and 0.1 to 5 parts by weight of a silica-based flow aid relative to 15 to 25 parts by weight of pranlukast, thus, even if the pranlukast content is reduced to 50 mg / tablet or less (one tablet each time, twice a day), the composition of the present invention can exhibit bioequivalent or even better pharmacokinetic characteristics than commercially available preparations in the human body, thereby improving the medication compliance of patients and improving the compliance of the patients. The side effect caused by excessive taking of pranlukast is reduced. The invention also discloses a preparation method of the pharmaceutical composition.

The invention discloses a preparation method of a pharmaceutical composition containing pranlukast and the pharmaceutical composition prepared by the preparation method.